The results of a double-blind study of the ocular hypotensive effect of low oral doses of nadolol (10, 20, 40, and 80 mg, once daily) in normal volunteers are reported.' Considerable dose related reductions (30% to 40%) of intraocular pressure (IOP) were obtained and were maintained for 24 hours with the 40 mg and 80 mg doses. There was a slight loss of effect after this time interval with the two lower doses, but reductions 20% or more were preserved. Previously published reports of the ocular hypotensive effect in normal subjects of oral propranolol and atenolol at corresponding or higher doses (40 mg b.d. and 50 mg b.d., respectively) showed IOP reductions of up to 25%.2 Thus, in view of what was considered to be an excellent IOP lowering potential of even low doses of nadolol, we have compared the efficacy of three regimens of once daily oral nadolol (20, 40, and 80 mg) with the two standard twice daily regimens of topical timolol (0-25% and 0.5%) in patients with chronic simple glaucoma.
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A further consideration in undertaking this study has been the growing awareness in recent years that an increasing number of patients in our glaucoma clinic population are receiving oral blockers for a variety of conditions. If Pi blockers, so administered, can reduce IOP to acceptable levels during chronic administration, then there is clearly a justification for rationalisation of therapy in these patients in the interests of good practice and safety, if not economy.
Material and methods

SUBJECTS
This was ar; open study conducted at two centres to compare the efficacy of three regimens of once daily, orally administered, nadolol (20, 40, and 80 mg) with that of twice daily, topically administered, timolol (0-25% and 0-5%) in the treatment of chronic simple glaucoma. Sixty eight patients (32 men and 36 women), mean age 59 years (range 29-81), were randomised to begin treatment with one of the three nadolol dosages o. Short-term. At the beginning of the short-term portion of the study the following baseline measurements were recorded: Goldmann applanation tonometry; pulse and blood pressure readings (after 5 min supine); visual acuity; accommodation; pupillometry; refraction; and Schirmer tear test. In addition the visual fields of both eyes of patients in the nadolol treatment groups were charted. At each weekly short-term visit patients returned approximately three to six hours after their morning medication for measurement of IOP, heart rate, and blood pressure. At the final short-term visit (4 weeks) measurements of the additional ocular parameters (except fields) were again taken. At any visit during short-term, if the IOP in either eye was greater than 21 mmHg, patients in the nadolol 20 mg or 40 mg treatment blood pressures, and heart rates were measured at monthly intervals with the same upward dosage titration provision as before. The additional ocular measurements (including fields) taken at the baseline visit was repeated at four-monthly intervals. The study protocol did not call for the long-term followup of timolol treated patients but, in the event, one of us (JW) did follow up a limited number of patients.
Statistical comparisons. Baseline characteristics of patients were compared by one way analysis of variance and Duncan's multiple range test. Changes in IOP were compared (where applicable) by one way analysis of covariance, which adjusts for pretreatment differences.
Results
IOP CONTROL-SHORT-TERM
All 68 patients randomised to treatment groups provided data suitable for evaluation. There were no statistically significant differences among the four initial treatment groups in terms of baseline IOPs, duration of prior glaucoma therapy, or numbers of patients previously requiring multiple drug therapy.
The mean age of patients randomised to 20 mg nadolol was, however, less than that of patients initially assigned to the 40 mg dose (p<005).
The clinical course of patients during four weeks of short-term therapy is shown in Fig. 1 Tables 2 and 3 illustrate the therapeutic outcome of short-term therapy (that is, control or lack of IOP control) according to initial and final dosage. A similar efficacy pattern was observed for the nadolol 20 mg and timolol 0-25% regimens, and for the nadolol 40 mg and 80 mg regimens. However, a majority of the seven patients titrated to the higher concentration of timolol did not show control of IOP.
Mean IOP reductions produced by the dose levels actually employed during weeks 1 and 4 are shown in Table 4 . Only those measurements at the end of week 1 provide a comparison of the randomly assigned starting doses, as they were obtained prior to any dose titration. At that time the mean 18-4% IOP reduction achieved with the 20 mg nadolol regimen was less (p<0.05) than that achieved with the nadolol 40 mg and 80 mg regimens (31-4% and 31% reductions, respectively) but not significantly different from the 0.25% timolol regimen (24-4% reduction).
If nadolol and timolol treatments are considered regardless of dosage, by the end of week four the mean IOP had decreased by 30-7% with nadolol from 27-9 mmHg to 19-1 mmHg, and by 34-6% with timolol from 26-6 mmHg to 17-8 mmHg.
DURATION OF IOP EFFECT
IOP measurements taken immediately prior to the next dose were obtained for all patients towards the end of week 4. Mean pressure reductions 23 to 24 hours after the last nadolol dose and 11 to 12 hours after the last timolol dose are shown in Table 5 . Statistical analyses were not made because the original randomisation scheme no longer applied but pressure reductions remained substantial at all dose levels. The TOPs of some patients on the 20 mg and tAdjusted for pretreatment differences. BLOOD PRESSURE AND HEART RATE Reductions in blood pressure and heart rate in patients receiving nadolol closely corresponded to those observed in the normal volunteer study.' Systolic pressure, diastolic pressure, and heart rate decreases ranged from 5 to 9%, 8 to 10% and 16 to 19%.
IOP CONTROL-LONG-TERM
The clinical course of the 38 patients (33 nadolol and 5 timolol) studied for up to two years is shown in Fig.  2 . At the last visit during this period (mean 12-3 months) 25 (76%) of the 33 patients on nadolol were controlled; two were discontinued as treatment failures on 40 mg daily without employing the option of a higher dose; and one was a treatment failure at the maximum dose. Of the five patients entering long-term therapy on timolol two were controlled at the final visit (mean 11.2 months), and the others were discontinued as treatment failures at the maximum 0-5% concentration. Table 6 illustrates the outcome (that is, control or lack of control) for patients on long-term nadolol therapy according to initial and final dosages. All but two of 23 nadolol patients entering long-term therapy on the 20 mg and 40 mg dosages were controlled by one or the other of these regimens, excluding four who were controlled but were discontinued because of adverse drug reactions. All five patients in one centre (J.W.) who were receiving 80 mg of nadolol at month 12 were reduced to a 40 mg dose and remained controlled at month 24. SAFETY Nadolol administered orally had no effect on visual acuity, accommodation, refraction, pupil size, or tear production. During the relatively brief period of this study there was no evidence of visual field deterioration in any patient.
The numbers of patients discontinued as a result of adverse reactions and the treatment regimens employed at the time of discontinuation can be seen Blood pressure and heart rate reductions for the three doses of nadolol used (20, 40, and 80 mg daily) corresponded closely to those obtained in the normal volunteer study.' In that study it was evident that, at the low doses of nadolol used, the ocular effect was considerably greater than the cardiovascular effects. This was not so obvious in our clinic patients, because baseline TOPs were not allowed to reach a maximum untreated level.
In most patients oral nadolol was well tolerated, and some expressed the wish to continue taking tablets rather than return to topical medication. A few patients did incur some of those side effects associated with I6 blockers, but at the 20 mg daily dosage level only one was discontinued for this reason ('slight tiredness').
Patient preference apart, we conclude that a 20 mg or 40 mg nadolol tablet taken once daily is sufficient to control the IOP of most patients with chronic simple glaucoma. This approach to therapy, we believe, would be preferable to topical medication in two situations; first, for reasons of practicality and cost in patients already receiving 3 blockers for cardiovascular indications and second, in patients for whom the instillation of eye drops is difficult or (without help) impossible. 
